To date, few studies have reported on EV-miRs as predictors of response to ICIs in NSCLC [14–16], mainly including small cohorts of patients treated with both PD-1 or PD-L1-based therapies as a first or second line, with consequent limited clinical application. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.